
Ionis Pharma (IONS) Stock Forecast & Price Target
Ionis Pharma (IONS) Analyst Ratings
Bulls say
Ionis Pharmaceuticals is a leader in the development of antisense technology, with a broad clinical and preclinical pipeline targeting a range of diseases. The company has a strong track record of successful partnerships, and its two independent launches in 2025 demonstrate its growing capabilities. However, Ionis has accumulated significant losses and may need to raise additional capital, posing a risk to profitability in the near term. With a current EV of ~$22.5B and a price objective of $115, the stock is a promising investment opportunity, but key risks include slower-than-expected uptake of TRYNGOLZA, regulatory setbacks, and potential spending delays hindering its 2028 cash-flow break-even target.
Bears say
Ionis Pharmaceuticals is a leading developer of antisense technology, with a broad and diverse pipeline targeting a range of diseases. However, the company's modest salesforce and focus on rare diseases may limit its ability to reach a significant number of patients and generate strong revenue. Additionally, recent approvals and upcoming launches may not meet previous peak-sales estimates due to potential challenges in patient identification and administration hurdles for certain drugs.
This aggregate rating is based on analysts' research of Ionis Pharma and is not a guaranteed prediction by Public.com or investment advice.
Ionis Pharma (IONS) Analyst Forecast & Price Prediction
Start investing in Ionis Pharma (IONS)
Order type
Buy in
Order amount
Est. shares
0 shares